Brucine Suppresses Malignant Progression of Prostate Cancer by Decreasing Sarcosine Accumulation Via Downregulation of GNMT in the Glycine/sarcosine Metabolic Pathway

Overview

Journal Cell Biochem Biophys

Specialties Biochemistry
Biophysics
Cell Biology

Date 2024 Jun 14

PMID 38877335

Authors

Long Miao

Yang Liu

Wei Chen

Chao Gao

Yijing Zhang

Jin Wei

Xiliang Cao

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) remains a leading cause of cancer-related incidence and mortality in men. Disruptions in amino acid (AA) metabolism contribute to the disease progression, with brucine, a glycine antagonist, exhibiting antitumor effects. This study explores the antitumor impact of brucine on PCa and investigates its mechanisms in regulating AA metabolic pathways. The study employed the PCa cell line DU-145, characterized by high sarcosine (Sar) levels, for various assays including Cell Counting Kit-8 (CCK8), wound healing, Transwell, 5-Ethynyl-2'-deoxyuridine (EDU), TdT mediated dUTP Nick End Labeling (TUNEL), flow cytometry, Western blot, and ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Network pharmacological analysis determined the anticancer mechanisms of brucine. Sar levels in DU-145 cells were significantly higher than in normal prostatic epithelial cells RWPE-1. Treatment with brucine resulted in a marked decrease in cell viability, proliferation, invasion, and migration, while promoting apoptosis in a dose-dependent manner. Sar levels decreased with increasing brucine concentration. Network pharmacology analysis linked brucine's anticancer effect to the AA metabolism and glycine N-methyltransferase (GNMT) pathways. GNMT expression in prostate cancer tissues and The Cancer Genome Atlas database was significantly elevated compared to controls. Treatment with brucine led to downregulation of GNMT expression in DU-145 cells without significant effect on sarcosine dehydrogenase (SARDH). Addition of recombinant GNMT partially reversed the inhibitory effects of brucine on DU-145 cells. Treatment with brucine downregulates GNMT expression in DU-145 cells, reducing Sar accumulation and inhibiting tumor progression. These findings provide new insights into the antitumor mechanisms of brucine in PCa.

References

Saeidi H, Ismail P, Samudi Raju C, Khairul-Asri M, Bakrin I . Genetic alterations in prostate cancer as diagnostic and prognostic markers. Malays J Pathol. 2023; 45(2):149-155. View

Washington C, Goldstein D, Moore A, Gardner Jr U, Deville Jr C . Health Disparities in Prostate Cancer and Approaches to Advance Equitable Care. Am Soc Clin Oncol Educ Book. 2022; 42:1-6. DOI: 10.1200/EDBK_350751. View

Liu J, Dong L, Zhu Y, Dong B, Sha J, Zhu H . Prostate cancer treatment - China's perspective. Cancer Lett. 2022; 550:215927. DOI: 10.1016/j.canlet.2022.215927. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Wang G, Zhao D, Spring D, DePinho R . Genetics and biology of prostate cancer. Genes Dev. 2018; 32(17-18):1105-1140. PMC: 6120714. DOI: 10.1101/gad.315739.118. View

Harris A, Metzler V, Lothion-Roy J, Varun D, Woodcock C, Haigh D . Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Front Endocrinol (Lausanne). 2022; 13:1006101. PMC: 9575553. DOI: 10.3389/fendo.2022.1006101. View

Zhang Q, Zhang P, Zhao Z, Wang J, Zhang H . Exploring the role of differentially expressed metabolic genes and their mechanisms in bone metastatic prostate cancer. PeerJ. 2023; 11:e15013. PMC: 10105558. DOI: 10.7717/peerj.15013. View

Zhang X, Xia B, Zheng H, Ning J, Zhu Y, Shao X . Identification of characteristic metabolic panels for different stages of prostate cancer by H NMR-based metabolomics analysis. J Transl Med. 2022; 20(1):275. PMC: 9205125. DOI: 10.1186/s12967-022-03478-5. View

Kdadra M, Hockner S, Leung H, Kremer W, Schiffer E . Metabolomics Biomarkers of Prostate Cancer: A Systematic Review. Diagnostics (Basel). 2019; 9(1). PMC: 6468767. DOI: 10.3390/diagnostics9010021. View

10.

Strmiska V, Michalek P, Eckschlager T, Stiborova M, Adam V, Krizkova S . Prostate cancer-specific hallmarks of amino acids metabolism: Towards a paradigm of precision medicine. Biochim Biophys Acta Rev Cancer. 2019; 1871(2):248-258. DOI: 10.1016/j.bbcan.2019.01.001. View

11.

Sreekumar A, Poisson L, Rajendiran T, Khan A, Cao Q, Yu J . Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009; 457(7231):910-4. PMC: 2724746. DOI: 10.1038/nature07762. View

12.

Huang Y, Lee C, Chen M, Chung M, Chang Y, Huang W . Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer Res. 2007; 13(5):1412-20. DOI: 10.1158/1078-0432.CCR-06-1551. View

13.

Dodt G, Kim D, Reimann S, Reuber B, McCabe K, Gould S . L-Pipecolic acid oxidase, a human enzyme essential for the degradation of L-pipecolic acid, is most similar to the monomeric sarcosine oxidases. Biochem J. 2000; 345 Pt 3:487-94. PMC: 1220782. View

14.

Song Y, Shiota M, Kuroiwa K, Naito S, Oda Y . The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer. Mod Pathol. 2011; 24(9):1272-80. DOI: 10.1038/modpathol.2011.76. View

15.

Khan A, Rajendiran T, Ateeq B, Asangani I, Athanikar J, Yocum A . The role of sarcosine metabolism in prostate cancer progression. Neoplasia. 2013; 15(5):491-501. PMC: 3638352. DOI: 10.1593/neo.13314. View

16.

Heger Z, Gumulec J, Cernei N, Polanska H, Raudenska M, Masarik M . Relation of exposure to amino acids involved in sarcosine metabolic pathway on behavior of non-tumor and malignant prostatic cell lines. Prostate. 2016; 76(7):679-90. DOI: 10.1002/pros.23159. View

17.

Lu L, Huang R, Wu Y, Jin J, Chen H, Zhang L . Brucine: A Review of Phytochemistry, Pharmacology, and Toxicology. Front Pharmacol. 2020; 11:377. PMC: 7145893. DOI: 10.3389/fphar.2020.00377. View

18.

Kang Q, Zheng K, Jiang G, Li Y, Liang Y, Geng Q . Brucine suppresses proliferation and promotes apoptosis of human cholangiacarcinoma cells via the inhibition of COX2 expression. J Cancer. 2023; 14(14):2700-2706. PMC: 10539398. DOI: 10.7150/jca.87514. View

19.

Yan W, Zeng Z, Qin F, Xu J, Liao Z, OuYang M . Effects of brucine on mitochondrial apoptosis and expression of HSP70 in prostate cancer cells. Transl Cancer Res. 2022; 11(3):500-507. PMC: 8990831. DOI: 10.21037/tcr-22-209. View

20.

Liu X, Yu C, Bi Y, Zhang Z . Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health. 2019; 172:70-80. DOI: 10.1016/j.puhe.2019.04.016. View